A small biotech firm has sparked controversy after using a series of settlement agreements secured from last year’s significant jury verdict success to seek a hefty $410 million award in the early part of next year. This daring move has sparked debate, as it exposes the company to claims that no genuine interest in purchasing its patents existed prior to court enforcement.
The legitimacy of the company’s demand and the corresponding reaction it has incited within legal and corporate circles raise several noteworthy questions. The main among them is how a company’s earlier legal victories and settlement agreements might influence not only future court decisions, but also its market standing. Particularly in regard to intellectual property rights.
With the bid now launched and the company subjected to increased scrutiny, the broader implications of this move for other firms with ongoing patent disputes remain to be seen.
For a more in-depth look at this unfolding story, visit the original report on Law360.